Registered Kenya · PPB

NEXGARD 136MG

AFOXOLANER

V2019/CTD5672/818ER AFOXOLANER 2.27% W/W GENERIC/BIOSIMILARS INN generic

What it does

Afoxolaner is a medication used primarily to treat and prevent flea and tick infestations in pets.

Commonly used for: flea infestation, tick infestation

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.

Source this medicine

Registration & product details

Registration no.
V2019/CTD5672/818ER
Registration date
2019-02-21 00:00:00
Expiry date
-
Status
Registered
Active ingredient
AFOXOLANER
Dosage form
AFOXOLANER 2.27% W/W
Strength
-
Pack size
1 CARTON BOX CONTAINING ONE BLISTER OF 3 CHEWABLE TABLETS
Therapeutic class
GENERIC/BIOSIMILARS
RxNorm RxCUI
1442093
Manufacturer / MAH
Nerix Pharma
Applicant / LTR
METROVET (K) LIMITED
Country of origin
FOREIGN
Manufacturer location
Alpha Centre, unit 51 & 52 Mombasa Road, Nairobi, Kenya

Source: Pharmacy and Poisons Board · fetched 2026-01-28 19:47:27 · updated 2026-08-03 02:56:32

Disclaimer: This information is sourced from Pharmacy and Poisons Board (Kenya). Always consult a qualified healthcare professional before using any medication.

About this medicine

Afoxolaner is a medication used primarily to treat and prevent flea and tick infestations in pets.

What it treats

  • flea infestation
  • tick infestation

How it works

Afoxolaner works by targeting the nervous system of fleas and ticks, leading to their death and helping to keep your pet free from these parasites.

Who it's for

This medication is suitable for dogs and cats that need protection against fleas and ticks.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: afoxolaner

BNF-referenced

Afoxolaner is an antiparasitic agent used primarily in veterinary medicine for the treatment of fleas and ticks in dogs. It is a member of the isoxazoline class of compounds, which act by inhibiting the insect nervous system, leading to paralysis and death of the parasites. Afoxolaner is administered orally and is known for its rapid onset of action and extended duration of efficacy against ectoparasites.

Indications

  • Flea infestations in dogs
  • Tick infestations in dogs
  • Control of parasitic infections caused by ectoparasites

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines.

Adults: The typical dose for dogs is 2.5 mg/kg body weight, administered orally once a month.

Mechanism of action

Afoxolaner acts by selectively inhibiting the glutamate-gated chloride channels (GluCl) and gamma-aminobutyric acid (GABA) receptors in the nervous system of insects and arachnids. This inhibition leads to hyperexcitation of the nervous system, resulting in paralysis and death of the parasites.

Pharmacodynamics

Afoxolaner is effective against various species of fleas and ticks. Its potency is primarily due to its selective binding to the specific receptors in the parasites' nervous system, which are not present in mammals, thus reducing the risk of toxicity to the host. The compound exhibits a favorable safety margin in dogs, and its pharmacodynamic profile allows for effective control of parasitic infestations.

Pharmacokinetics

Afoxolaner is well absorbed after oral administration, with peak plasma concentrations occurring within 4 to 8 hours. It has a high volume of distribution and is extensively metabolized in the liver. The elimination half-life is approximately 2 weeks, allowing for sustained efficacy against parasites. Afoxolaner is primarily excreted through feces and urine, with a minor fraction remaining unchanged.

Adverse effects

  • Vomiting
  • Diarrhea
  • Anorexia
  • Lethargy
  • Ataxia

Precautions

  • Use with caution in animals with a history of seizures.
  • Monitor for any signs of adverse reactions, especially in sensitive populations.

Pregnancy

Safety in pregnant animals has not been established. Use only if the benefits outweigh the risks.

Breast-feeding

Safety in lactating animals has not been established. Use only if the benefits outweigh the risks.

Storage

Store at room temperature, away from moisture and direct sunlight.

Formulations

  • Oral chewable tablets
  • Topical solution
PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: afoxolaner

PubChem CID 25154249

Molecular formula: C26H17ClF9N3O3

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.

Ghana 4 products